← Back to News
Regulatory

Navigating the Regulatory Landscape for Molecular Authentication

The regulatory environment surrounding supply-chain traceability is undergoing the most significant transformation in a generation. From the European Union's sweeping Digital Product Passport initiative to the US FDA's Drug Supply Chain Security Act, enterprises operating across global supply chains face an increasingly demanding web of provenance documentation, due-diligence, and serialisation requirements. This guide provides a practical overview of the key frameworks relevant to molecular authentication deployments and offers a compliance checklist for enterprise buyers evaluating traceability technology investments.

European Union: A Regulatory Ecosystem in Transformation

The European Union has moved further and faster than any other regulatory jurisdiction in mandating supply-chain transparency. Three overlapping legislative frameworks — the Digital Product Passport, the EU Deforestation Regulation, and the Corporate Sustainability Reporting Directive — together create a comprehensive compliance imperative for any enterprise selling into, manufacturing within, or sourcing materials from EU markets.

EU Digital Product Passport (DPP): Timeline 2027–2030

The Digital Product Passport is the centrepiece of the EU Ecodesign for Sustainable Products Regulation (ESPR), which entered into force in July 2024. The DPP is a data carrier — most likely a QR code or data matrix — attached to or embedded in each product unit, providing access to a standardised digital record of the product's composition, origin, environmental performance, recyclability, and supply-chain history. The DPP is explicitly designed to be machine-readable and to support automated verification by customs authorities, market surveillance bodies, and other downstream actors in the supply chain.

The rollout timeline is sector-specific:

Molecular authentication is well positioned to provide the verified, tamper-resistant provenance data that underpins DPP compliance. A DNA marker applied at the point of material production, with authentication events recorded in a blockchain or signed-record platform such as TraceCloud, creates an independently auditable chain of custody that can populate the material origin and composition fields of the DPP with data that cannot be retrospectively altered.

EU Deforestation Regulation (EUDR)

The EU Deforestation Regulation (Regulation EU 2023/1115), adopted in June 2023 and entering full enforcement on 30 December 2025 for large operators, prohibits the placing on the EU market of seven commodities — cattle, cocoa, coffee, palm oil, soya, wood, and rubber — and derived products if they are associated with deforestation or forest degradation occurring after 31 December 2020. Operators must conduct due diligence demonstrating that covered products were produced on land that was not subject to deforestation after that date.

The regulation requires collection of geolocation data for the plots of land where commodities were produced, documentation of compliance with the laws of the country of production, and a risk assessment supported by traceability data. Molecular authentication directly supports the commodity-level traceability required for EUDR due diligence: DNA markers applied at origin (farm, plantation, or forest concession) create a verifiable link between the commodity lot and its specific geographic origin, enabling importers to confirm that lots originate from the declared non-deforested plots.

For coffee — one of the seven regulated commodities and a major application area for Haelixa — the combination of DNA marker authentication with GPS geolocation data collected via the TraceCloud mobile application provides a robust EUDR compliance package. Enterprise customers in the coffee sector should note that SME operators have an additional twelve months before EUDR enforcement applies, with full enforcement for all operators expected from June 2026.

CSRD: Due Diligence and Scope 3 Reporting

The Corporate Sustainability Reporting Directive (CSRD), which replaced the Non-Financial Reporting Directive (NFRD) and entered into force in January 2023 with phased reporting obligations beginning in 2025, requires in-scope companies to report on their environmental, social, and governance impacts across the full value chain — including Scope 3 upstream supply-chain emissions, biodiversity impact, and social due diligence in accordance with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights.

The European Sustainability Reporting Standards (ESRS) developed under CSRD specifically require disclosure of material supply-chain risks and the due-diligence processes used to identify and mitigate them. For companies sourcing from regions at risk of human rights violations, environmental non-compliance, or fraud, authenticated traceability data provides the evidentiary basis for ESRS disclosures on upstream due diligence. The ability to demonstrate that provenance claims are supported by molecular authentication — rather than solely by supplier self-declarations — is increasingly viewed by auditors and sustainability rating agencies as a meaningful differentiator in CSRD disclosure quality assessments.

United States: FDA Serialization and DSCSA

The US Drug Supply Chain Security Act (DSCSA), enacted in 2013 with a decade-long implementation timeline, reached its final and most demanding phase in November 2023: interoperable, electronic, lot-level tracing of prescription drug products from manufacturer to dispenser. DSCSA requires pharmaceutical manufacturers, wholesale distributors, repackagers, and dispensers to exchange standardised transaction data (Transaction Information, Transaction History, and Transaction Statement) for every covered drug product unit, and to be capable of conducting "enhanced drug distribution security" — product verification at the individual package level — by November 2025.

Molecular authentication complements the DSCSA serialisation framework in two important ways. First, DNA markers applied during pharmaceutical manufacturing provide a physical authentication layer that is independent of — and therefore not subvertable by compromising — the digital serialisation data. Second, in clinical trial and investigational product contexts where DSCSA's requirements are less prescriptive, molecular authentication provides a validated method for confirming that investigational materials are authentic and uncompromised.

The FDA has also signalled, through its guidance on Pharmaceutical Quality Systems (ICH Q10) and its Technology Modernization Action Plan, a strong interest in emerging technologies that enhance supply-chain integrity. Companies seeking to use molecular authentication as a component of their drug product quality system are advised to consult with their regulatory affairs team and, where appropriate, to discuss the approach with the relevant FDA review division at the pre-IND or pre-submission stage.

ISO 17025 Accreditation for Testing Laboratories

ISO/IEC 17025:2017 is the international standard for the competence of testing and calibration laboratories. For molecular authentication to be used as the evidential basis for regulatory compliance decisions — such as EUDR due-diligence reports, DSCSA transaction verification, or customs fraud enforcement — the testing laboratory conducting authentication assays must typically be ISO 17025 accredited for the specific test methods used.

Haelixa's detection methodology for molecular markers has been validated to ISO 17025 standards by two external accredited laboratories (details available to enterprise customers). For customers establishing in-house testing capabilities, Haelixa provides a full method validation package — including measurement uncertainty estimates, linearity studies, robustness testing, and method transfer protocols — that supports the analytical laboratory's own accreditation submission to national accreditation bodies (UKAS in the UK, DAkkS in Germany, COFRAC in France, SAS in Switzerland).

Key elements of an ISO 17025 submission for a DNA marker detection method include: a clearly defined scope of the test method (substrate types, concentration range, claimed limits of detection and quantification); a full validation report covering selectivity, specificity, linearity, precision (repeatability and intermediate precision), trueness, and robustness; a documented quality control procedure including use of certified reference materials or in-house controls at defined intervals; and a measurement uncertainty budget. Haelixa's application support team can assist customers in preparing these elements.

Swiss Regulatory Context

Switzerland, where Haelixa is headquartered, has a well-developed regulatory framework for product authenticity and traceability, overseen by the Federal Food Safety and Veterinary Office (FSVO/BLV) for food and agricultural applications and by Swissmedic for pharmaceutical and medical device applications. The Swiss equivalents of EU food law (Lebensmittelgesetz, LMG) and pharmaceutical law (Heilmittelgesetz, HMG) are closely aligned with EU frameworks through bilateral agreements and autonomous harmonisation.

Switzerland has been among the early adopters of molecular authentication technology for food and agricultural traceability. The Swiss Federal Office for Agriculture (FOAG/BLW) has endorsed the use of DNA-based provenance documentation in the context of the geographic indication (GI) protection regime for Swiss agricultural products, including Gruyère AOP, Appenzeller cheese, and several Swiss wine designations. Haelixa's experience in the Swiss regulatory environment informs our approach to regulatory engagement in EU and US markets, and we work proactively with customers to navigate multi-jurisdictional compliance requirements.

Compliance Checklist for Enterprise Buyers

Companies evaluating molecular authentication technology investments should work through the following checklist before final procurement decisions:

  1. Regulatory scope mapping: Identify which regulatory frameworks apply to your specific products and supply chains. Not all frameworks apply to all sectors — DSCSA is pharmaceutical-specific, while EUDR applies to the seven listed commodities only. A clear regulatory scope map prevents both under-investment (missing a compliance requirement) and over-investment (building capabilities beyond what is required).
  2. Timelines and enforcement dates: Map your deployment timeline against regulatory enforcement dates for each applicable framework. EUDR enforcement for large operators is December 2025; DSCSA enhanced drug distribution security is November 2025; EU DPP for batteries is February 2027; EU DPP for textiles is expected 2027. Allow 12–18 months for enterprise deployment, validation, and staff training.
  3. Substrate compatibility validation: Confirm that the molecular authentication technology under evaluation has been validated for your specific substrate type (fibre, oil, powder, polymer, etc.) and processing conditions. Request full validation data including marker stability under your specific process conditions.
  4. Detection infrastructure: Assess where in your supply chain authentication events need to occur (at origin, at manufacturing, at distribution, at retail) and confirm that field-deployable detection equipment is available and appropriate for each environment.
  5. Data management and integration: Confirm that the traceability platform provides data in formats compatible with your ERP, WMS, or compliance reporting systems, and that API documentation is available for integration development.
  6. Laboratory accreditation: If authentication results will be used as regulatory evidence, confirm that the testing laboratory is ISO 17025 accredited for the relevant method, or obtain the method validation package needed to support your own accreditation submission.
  7. Supplier engagement: Identify the upstream supply-chain nodes where markers will be applied and begin engagement with those suppliers early. Authentication programs that require marker application at tier-2 or tier-3 suppliers need adequate lead time for supplier training, equipment installation, and process validation.
  8. Legal and contractual framework: Establish contractual obligations for marker application and custody chain maintenance with each supplier node. Define responsibilities for re-testing, dispute resolution, and data ownership in the event of an authentication failure.

The regulatory trajectory is clear: supply-chain traceability requirements are expanding in scope, deepening in technical detail, and accelerating in enforcement. Companies that begin building verified traceability infrastructure now will be better positioned to meet the compliance requirements of the next five years than those that wait for final regulatory deadlines. Molecular authentication offers the verification rigour that the new generation of traceability regulations demands — and Haelixa's team is ready to support your compliance journey.

Published by the Haelixa Editorial Team ·